BLAKE KATRYN 4

What Happened
Blake Katryn, a non-employee director of Twist Bioscience (TWST), received an annual equity award of 5,095 shares on February 5, 2026. The Form 4 reports the acquisition as an award (transaction code A) at $0.00 per share (total reported value $0). This was a compensation grant, not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-05 (reported on Form 4 filed 2026-02-09). Filing was timely (within the two-business-day Form 4 window).
• Transaction type/code: Award/grant (A). Price reported: $0.00 per share.
• Shares granted: 5,095 shares. Total reported consideration: $0.
• Shares owned after transaction: not specified in this filing.
• Vesting/footnote: F1 — 100% of the shares vest on the earlier of (i) the one-year anniversary of the grant or (ii) the first annual meeting of stockholders after the grant date, provided the director remains a service provider.
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in this filing.

Context
This award is a standard director compensation grant and does not represent an open‑market buy or sell. Because vesting is conditional on continued service and a future date, the shares may not be freely owned or tradable immediately. Such grants are common and intended as compensation; they should not be interpreted on their own as a bullish or bearish signal.